<SEC-DOCUMENT>0001193125-13-367944.txt : 20130916
<SEC-HEADER>0001193125-13-367944.hdr.sgml : 20130916
<ACCEPTANCE-DATETIME>20130916163126
ACCESSION NUMBER:		0001193125-13-367944
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130910
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130916
DATE AS OF CHANGE:		20130916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS, INC.
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16133
		FILM NUMBER:		131099193

	BUSINESS ADDRESS:	
		STREET 1:		566 QUEENSBURY AVENUE
		CITY:			QUEENSBURY
		STATE:			NY
		ZIP:			12804
		BUSINESS PHONE:		(518) 743-8892

	MAIL ADDRESS:	
		STREET 1:		566 QUEENSBURY AVENUE
		CITY:			QUEENSBURY
		STATE:			NY
		ZIP:			12804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DELCATH SYSTEMS INC
		DATE OF NAME CHANGE:	19990607
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d598759d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of report (Date of earliest event reported): September&nbsp;16, 2013 (September 10, 2013) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>DELCATH SYSTEMS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-16133</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>06-1245881</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>566 Queensbury Avenue, Queensbury, New York, 12804 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(518) 743-8892 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NONE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Delcath Systems, Inc. (the &#147;Company&#148;) announced on September&nbsp;13, 2013 that the Company&#146;s Board of Directors has implemented a leadership transition plan under which Jennifer Simpson, Ph.D., M.S.N.,
C.R.N.P. (age 45), the Company&#146;s current Executive Vice President, Global Head of Business Operations, and Graham Miao, Ph.D., M.S., MBA (age 49), the Company&#146;s current Executive Vice President and Chief Financial Officer, have been
appointed to serve as Interim Co-President and Co-Chief Executive Officers. In addition to her role as Interim Co-President and Co-Chief Executive Officer, Dr.&nbsp;Simpson shall continue to serve as the Company&#146;s Executive Vice President,
Global Head of Business Operations. In addition to his role as Interim Co-President and Co-Chief Executive Officer, Dr.&nbsp;Miao shall continue to serve as the Company&#146;s Executive Vice President, Chief Financial Officer. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The employment of Eamonn P. Hobbs as President and Chief Executive Officer with the Company was terminated as of September&nbsp;10, 2013; Mr.&nbsp;Hobbs has also resigned from the Board of Directors. Mr.&nbsp;Hobbs is
expected to receive certain severance payments pursuant to his employment agreement with the Company dated August&nbsp;10, 2011. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Simpson joined Delcath in 2012, and has an extensive background in pharmaceutical and oncology product development, clinical trials and global marketing. Prior to her appointment at&nbsp;Delcath,
Dr.&nbsp;Simpson served as the Vice President, Global Marketing, Oncology Brand Lead at&nbsp;ImClone Systems, Inc.&nbsp;(a wholly- owned subsidiary of&nbsp;Eli Lilly and Company). In this role, she was responsible for all product commercialization
activities and launch preparation for one of the late stage assets. While at ImClone, Dr.&nbsp;Simpson also held various positions of increasing responsibility including serving as the Vice President, Product Champion and the Associate Vice
President, Product Champion. Previously, Dr. Simpson held several leadership positions at Ortho Biotech (now Janssen Biotech), a Pennsylvania-based biotech company that focuses on innovative solutions in immunology, oncology and nephrology. Prior to
her time at Ortho Biotech, Dr.&nbsp;Simpson spent over a decade as an oncology-nurse practitioner and educator. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Miao joined Delcath in 2011 as Executive Vice President and Chief Financial Officer and is a senior financial executive with extensive experience in global business operations, financial planning and analysis,
and business development in&nbsp;the United States,&nbsp;Asia&nbsp;and&nbsp;Europe. Previously, he served as Chief of Staff of the Global CFO Organization and member of the Financial Leadership team of Dun&nbsp;&amp; Bradstreet Corporation. Prior to
joining Dun&nbsp;&amp; Bradstreet, Dr.&nbsp;Miao was Executive Vice President&nbsp;&amp; CFO of Pagoda Pharmaceuticals&#151;a&nbsp;Shanghai-based specialty pharmaceuticals and medical device company focused in urology and allergy. In addition,
Dr.&nbsp;Miao has held various leadership positions, including division CFO roles, with Symrise, Inc., Schering-Plough Corporation and Pharmacia Corporation, and served as a biotech equity analyst with J.P. Morgan. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In addition, under the transition plan, Gabriel Leung has been appointed Chairman of the Board. He replaces Dr.&nbsp;Harold Koplewicz as Chairman, who remains a member of the Board of Directors. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Leung joined the Delcath Board of Directors in March 2011, and holds a wealth of experience in successfully gaining regulatory approval for and launching oncology drugs. Mr.&nbsp;Leung previously served as
President of the Pharmaceuticals Business at OSI Pharmaceuticals, overseeing its oncology, diabetes and obesity businesses prior to the Company&#146;s acquisition by Astellas Pharma Inc. in June 2010. Prior to OSI, Mr.&nbsp;Leung served as Group
Vice President, Global Prescription Business&nbsp;&amp; Head of the Global Oncology Franchise for Pharmacia Corporation. Previously, Mr.&nbsp;Leung held several leadership positions at Bristol-Myers Squibb. Currently, Mr.&nbsp;Leung serves on the
Board of Directors of Albany Molecular Research, Inc., and is Executive Vice Chairman of the Board and Chair of the Global Commercialization Team of Novocure, Ltd., a privately-held oncology medical device company. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Board has also appointed a Transition Committee to assist the Board and management with the leadership transition including the search process for the next President and Chief Executive Officer of the Company. This
Committee will also assist the Board in its rigorous evaluation of potential strategic options for the Company going forward. The initial members of this committee are current Board members Douglas Watson and Roger Stoll, as well as
Dr.&nbsp;Koplewicz and Mr.&nbsp;Leung. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;13, 2013, the Company issued a press release announcing the above matters, a copy
of which release is filed as Exhibit 99.1 to this Form 8-K and which is incorporated by reference herein. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following exhibit is filed herewith: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Delcath Systems, Inc., dated September 13, 2013</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3">DELCATH SYSTEMS, INC.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: September&nbsp;16, 2013</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter J. Graham</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Peter J. Graham</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Executive Vice President, General Counsel</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>Exhibit<BR>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Description</B></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Delcath Systems, Inc., dated September 13, 2013</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d598759dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g598759image001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DELCATH SYSTEMS BOARD OF DIRECTORS IMPLEMENTS LEADERSHIP TRANSITION PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Jennifer Simpson and Graham Miao Appointed Interim Co-President and Co-Chief Executive Officer; Gabriel Leung Appointed Chairman of the
Board of Directors </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY &#150; September&nbsp;13, 2013 &#150; Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and
medical device company focused on oncology, announced today that the Company&#146;s Board of Directors has implemented a leadership transition plan under which Jennifer Simpson, Ph.D., M.S.N., C.R.N.P., the Company&#146;s current Executive Vice
President, Global Head of Business Operations, and Graham Miao, Ph.D., M.S., MBA the Company&#146;s current Executive Vice President and Chief Financial Officer, have been appointed to serve as Interim Co-President and Co-Chief Executive Officers.
The employment of Eamonn P. Hobbs as President and Chief Executive Officer with the Company was terminated as of September&nbsp;10, 2013; Mr.&nbsp;Hobbs has also resigned from the Board of Directors. In addition to her role as Interim Co-President
and Co-Chief Executive Officer, Dr.&nbsp;Simpson shall continue to serve as the Company&#146;s Executive Vice President, Global Head of Business Operations. In addition to his role as Interim Co-President and Co-Chief Executive Officer,
Dr.&nbsp;Miao shall continue to serve as the Company&#146;s Executive Vice President, Chief Financial Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the transition plan,
Gabriel Leung has been appointed Chairman of the Board. Mr.&nbsp;Leung has been a member of the Board of Directors since 2011 and brings more than 20 years experience in the oncology pharmaceuticals marketplace to Delcath. He replaces
Dr.&nbsp;Harold Koplewicz as Chairman, who remains a member of the Board of Directors. The Board has also appointed a Transition Committee to assist the Board and management with the leadership transition including the search process for the next
President and Chief Executive Officer of the Company. This Committee will also assist the Board in its rigorous evaluation of potential strategic options for the Company going forward. The initial members of this committee are current Board members
Douglas Watson and Roger Stoll, as well as Dr.&nbsp;Koplewicz and Mr.&nbsp;Leung. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The Delcath Board of Directors believes these actions are in the
best interests of the Company and its shareholders. I look forward to working with the senior management team and the Board Transition Committee as we evaluate our strategy and develop our implementation plan,&#148; said Mr.&nbsp;Leung. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Background on Drs. Simpson and Miao, Mr.&nbsp;Leung </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Simpson joined Delcath in 2012, and has an extensive background in pharmaceutical and oncology product development, clinical trials and global
marketing. Prior to her appointment at&nbsp;Delcath, Dr.&nbsp;Simpson served as the Vice President, Global Marketing, Oncology Brand Lead at&nbsp;ImClone Systems, Inc.&nbsp;(a wholly- owned subsidiary of&nbsp;Eli Lilly and Company). In this role,
she was responsible for all product commercialization activities and launch preparation for one of the late stage assets. While at ImClone, Dr.&nbsp;Simpson also held various positions of increasing responsibility including serving as the Vice
President, Product Champion and the Associate Vice President, Product Champion. Previously, Dr. Simpson </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
held several leadership positions at Ortho Biotech (now Janssen Biotech), a Pennsylvania-based biotech company that focuses on innovative solutions in immunology, oncology and nephrology. Prior
to her time at Ortho Biotech, Dr.&nbsp;Simpson spent over a decade as an oncology-nurse practitioner and educator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Miao joined Delcath in 2011
as Executive Vice President and Chief Financial Officer and is a senior financial executive with extensive experience in global business operations, financial planning and analysis, and business development in&nbsp;the United
States,&nbsp;Asia&nbsp;and&nbsp;Europe. Previously, he served as Chief of Staff of the Global CFO Organization and member of the Financial Leadership team of Dun&nbsp;&amp; Bradstreet Corporation. Prior to joining Dun&nbsp;&amp; Bradstreet,
Dr.&nbsp;Miao was Executive Vice President&nbsp;&amp; CFO of Pagoda Pharmaceuticals&#151;a&nbsp;Shanghai-based specialty pharmaceuticals and medical device company focused in urology and allergy. In addition, Dr.&nbsp;Miao has held various
leadership positions, including division CFO roles, with Symrise, Inc., Schering-Plough Corporation and Pharmacia Corporation, and served as a biotech equity analyst with J.P. Morgan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Leung joined the Delcath Board of Directors in March 2011, and holds a wealth of experience in successfully gaining regulatory approval for and
launching oncology drugs. Mr.&nbsp;Leung previously served as President of the Pharmaceuticals Business at OSI Pharmaceuticals, overseeing its oncology, diabetes and obesity businesses prior to the Company&#146;s acquisition by Astellas Pharma Inc.
in June 2010. During his seven years at OSI, Mr.&nbsp;Leung held several senior management positions, led the successful filing of two supplemental New Drug Applications (NDA) for Tarceva(R) (erlotinib) and guided it to one of the most successful
launches in the U.S. oncology marketplace. During Mr.&nbsp;Leung&#146;s tenure, OSI&#146;s market capitalization increased from $1.4 billion to approximately $4.0 billion at the time of acquisition. Prior to OSI, Mr.&nbsp;Leung served as Group Vice
President, Global Prescription Business&nbsp;&amp; Head of the Global Oncology Franchise for Pharmacia Corporation. At Pharmacia, Mr.&nbsp;Leung served on the CEO&#146;s Corporate Operating Committee, overseeing the global oncology franchise and all
oncology clinical development projects and the discovery portfolio strategy that led to four successful ODAC panel recommendations and NDA/sNDA approvals. Previously, Mr.&nbsp;Leung held several leadership positions at Bristol-Myers Squibb.
Currently, Mr.&nbsp;Leung serves on the Board of Directors of Albany Molecular Research, Inc., and is Executive Vice Chairman of the Board and Chair of the Global Commercialization Team of Novocure, Ltd., a privately-held oncology medical device
company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>About Delcath Systems </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary drug/device combination product, the
Delcath Hepatic Delivery System, is designed to administer high dose chemotherapy and other therapeutic agents to the liver, while controlling the systemic exposure of those agents. The Company&#146;s initial focus is on the treatment of primary and
metastatic liver cancers. Outside of the United States, our proprietary product to deliver and filter melphalan hydrochloride is marketed under the trade name Delcath Hepatic CHEMOSAT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
Delivery System for melphalan hydrochloride. The Company obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT Delivery System for Melphalan in April 2012. The right to affix the CE mark allows the Company to market and sell the
CHEMOSAT Delivery System for Melphalan in Europe. In addition, the Company has initiated plans to investigate the Melblez Kit for primary liver cancer. For more information, please visit the Company&#146;s website at www.delcath.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news
release contains forward-looking statements, which are </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to,
uncertainties relating to: the leadership transition plan and its impact on the Company, the Company&#146;s ability to satisfy the requirements of the FDA&#146;s Complete Response Letter and provide the same in a timely manner, clinical adoption,
use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in Europe, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with
primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets, the timing and results of future clinical trials including without limitation the HCC trials, approval of the current or
future chemosaturation system for delivery and filtration of melphalan, doxorubicin or other chemotherapeutic agents for various indications in the US and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, our ability to
successfully enter into strategic partnership and distribution arrangements in foreign markets including Australia and key Asian markets and timing and revenue, if any, of the same, uncertainties relating to the timing and results of research and
development projects,, and uncertainties regarding our ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our
filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after the date they are made. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Contact Information:</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor Contact:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Media Contact:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Michael Polyviou/Patty Eisenhaur</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">John Carter</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EVC Group</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">212-850-6020/951-316-0577</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EVC Group</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">212-850-6021</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>### </B></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g598759image001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g598759image001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4`$5`P$1``(1`0,1`?_$`,0```("`@,!`0$`````
M```````)"`H&!P$%"P,"!`$!``$%`0$!``````````````<!`@0%!@,("1``
M``8!`P("!P8#!`4-`````0(#!`4&!P`1""$2$PDQ02(4E!<*T>(C%59743(6
M87$S)(&AL4(WP>%B)4:&UB='EQA8&A$``0($!`('!P("!@D%`0```0(#`!$$
M!2$Q$@9!!U%A<9$34Q2!H=$B,E(5L<'P0N%BTB,D%W*2HK+",T.358)S-%0E
M%O_:``P#`0`"$0,1`#\`O\:0BKEYM'U!.3_+?Y<.^-E4XWT/)\2WQW3KN6TV
M&]V"OR!W%G4ER+,!CHV%?M@1:?EI>T_B=Q^X=P#;4S;&Y74>[;'^7?JW65^*
MI&E*$J'RRQF2,YQ&.Z]_5.W;J;<U3H=2&TJF5*!^:>$@.J%F_P#Z_LZ?_2S$
MW_NM;_\`POKLO\AK9_Y"H_[2?[4<U_FY6?\`TF_]=7PCZ(?5_9M%9+WGA7BW
MW;Q">.*&5K6*_A;AWBB"E9*F*G;Z.X0#?TZM/(:WR,KB]JX3;3+_`'HJ.;E7
M/&C:E_IJ^$.)\OWZD;B/S&NU>P_DJ!F^..5[.Y2C:Z2WOH][0++,+B0C>*C+
M8@L4D<_>+'\-!)\1$5E-BE$1$`UP.Z>4=^V_3KKJ12:NA;$U:00M(Z2GB.DI
M)E'7V#F+:;P\FDJ`:>J49#5+03T!7#'`3`G%C$!`0`0$!`0W`0Z@(#ZP'^&H
MGB0XYTA!I"#2$)=\Z#S4;;Y6.,,-7RGXCKN7'^5+O/U1>.LEDDZTTB&T'#-)
M07B3B+CY%9RNN=V!`()2E``WWU(/+W93.]:VHI7WUL)9;2H%*0J942,9D=$<
M=O'=#NUZ9E]II+JG5E,B2)2$^$*[\NSZDO,W./F!B'C)*<5<=4F*R/)OFTI:
MHC(=FF)&&81S%5\Y=M8YW7VK9RH4B>VQU"EZ^G79[LY1T&V["_>&ZUUQ;(!"
M2VD`DF4IA1CF-O<Q:R]W9JW*I6T)<5(D*42!(F>75%N4!WU!0B6!E'.JP@TA
M!I"#2$&D(-4,^$(CCR"Y=\9>*D8SEN16;\=8A;2:#ES$)W6R,(=[,)-!`JP1
M#!PJ#R2.0X@79(AO:';6WM=AO%[446FF>?(ST))"9])R$:ZX7>V6M(5<'FV@
M<M1`)[!QB.7$3S4^'?.G*EZQ-QGND]?YG'5;8V>S3A:I+154282+]:.:)L9J
M1212D'*CA`WLIEV[0WWUMK[LF_[:HFJZ\MI:;=64I&H%4P)F8&4:^T[HM-[J
METMM6IQ;:9J,B!*<LSG&V.??)^0X9<0\X<F(FKL+I*XHJ*UACJM*/W49'S3T
M'39JW9/)!DW=.FB"AW`=QR)F$`#T:P=L69&X+]36=Q9;0^YI*@`2!*<P#('L
MC*OMS59[2_<D)"U-(F$G`'M/"*B\%]71GR?FX:#9\*\3B[FY6/BFN^5;AU7D
M72+1'H%7$?\`$6#4ZN<B[8TVIQ5Q?DE))_NT\,?NB)T<V:UQ00FC:F2!]:LY
MRZ(O*0$@XE8*$E'2!&KJ2B8U^Z:I',HFV7>,D7"R":ABE.<B*J@E`1`!$`ZA
MKYO=2&WE-IQ2%$`]AB;&U:T)4<R`>^.WU9%\&D(-(0:0@TA!I"#2$&D(-(0:
M0@TA!I"#2$>:9]3]("^\U.T)"D"01V$L3L2F`PF\8I26!QXI@$`[3;N1#8-P
M]D-?7O)M.G9*2.-0X>SZ?A'S?S-.K<ZNII`_7XQVWT_'E>\;O,DL')QMR/)?
M#QF)H;&2U5+2IY&NB9_;GER3E3/G2\7*%=>$C`(=B8%*)>X1$>H:\^:6\[MM
M%JC-H+>M]3FO6DJP2$2EB)9F+M@;8MVXW*G\CXFEI*-.DZ<5%4YX'@!#F>;O
MTL'&YMA.Y7+A]=\EU;*U,KLK88RK7Z;C;55KM^4-%WZL(=PA$1$A"2+U)$2(
M."F73!3M`R>P]P1_MSG5>%7)NGOK;*Z%Q825(!2I$S+5+401TC`]<=E>^5]N
M31+>M+CJ:I"2K2LA252QED"#T2GUB*(:Z,G!R:S=8KF+F8:0405((F1>1LK&
M.3)J%[BCW(NF3Q`0W`=RG+KZ3"DNHF"%-J'L(/QB#R%-+D<%)/9'JL^21RKL
M/+SRXL"9'NTBO+7^N13_`!G>)5VL+AW*3%$=GAVDN^<&V.N^E8%-HX7.;J99
M0PCOOOKXKYBV5JQ;MJ:6F`32K4'$`9`+$R!U!4P.J/J+9=T7=MO,5#Q*GT`H
M4>DI,@3UD2)A;GF.?4T8-XIW^Q85XUT)'D=D:J/%XFUVM>?&"Q?`3+<_ANHR
M/E&+60?VQXP4`2K"W*BU`X"!5S[:Z[:G)^Y7JC3<KN[Z6E6`4I`FXI)XD$@)
M!X3QZHYS<7,FBM3ZJ.W(%14),E*)D@'B`<2KV83XPFYM]6SS=)()KN\`\=5X
MD%Q.=D@UOK9VHWWZ()R)[4X2(J`=!4\`P>OM]6I`/(S;>F2:JLURS^27;+2/
MU]L<>.:]ZU`FGI_#GT+_`%U?M%@WRKOJ`\$>8;;V6$+S4E,"\AI!HX<UZL/)
M@DW3K][DB=P\:5&PJMV#D)Q!JD=<6+E`ASI%$4CJ=I@"*][<KKGM6G-RI7!4
MVD'YE`24B>16G'">$P<\Y1WVU]^T.X'11/H\"X'Z1.:5R^TX8]1]DY0N?ZP&
M6`N)N$\&150IULDY7DET.W\)1)*KUE!N<Q]OYR*"?IOZ]=;R&1_CK@X<O":'
M^THG]HT'-I0]'2(XZEGW($))^FCKI+!YLN(EEB=Z-?QWEZ=,80(/AKMJBY(T
M,!3;;;N%`#<.H:D/F^ZIK9+\LU.M)]A6/A'%<MD!>Z&@<@E9[DGXQ?:\PSS(
MN/'EN8B)DS-LH[?3<\HYC\>8UKONSBXWN902[SHQS5=9%-G$,1.07CY801;E
M,`>TH8A#?,VU-H77=U>:.V@!I.+CBL$('6>)/!(Q/OB==P[BM^W*3U-:9N*,
MDH$M2CU##`<3D/=%0Z__`%<G*N1GW:V,N->$JO6/%5!BPM\C<+9,F0`VR)W,
MA%R=7:`L8H;F*1`0`1V`1`-]3K2\B[*EL"LJZE;O$H"$CV`A1[S$25'-BZEP
M^FIV$-<`HJ4?:04_I$IN`'U.W(/D=RGP5QWR]Q^Q,TB<R9$A*&YM]*E[3#NZ
MV$R=5,LHG$2BU@2DQ1.0OX0K([@/\P:TNZ.3MJM-EJ;M053Y73M*6$K"2%2X
M3`3+MQ[(VU@YE5]QN;-!5L,A#KB4ZDE0E,RG+&>>6$68/,:YS5?R[^+=NY*V
MJI2%[1K\M7(&+J$7)-XEW-RMDEVT6W2"1=(N$VJ#4BQEU3`FH8$TQV*.H?VG
MMM[=5Z;M#+@:U)4HJ(G()$S@,SE+*)'W#>V]OVQ=R<05A)2`D&4RHRSQE%1*
M]_5T\E99RM\L.*.)JRS[S%;#:;-;KFY,0#B)3K!%)55,IQ2#J4NX`/K'4[4O
M(NSH3_C*Y]:N.E*4=T]41*]S8N2S_AJ5E(ZU*5_9C&*A]7#R^CYMNM>^-V"+
M'`D53!Y&5YY=:K**)]X>*"$F_E[*@DIX>^P&:F#?TZ]ZCD985-RIJNJ0Z<BH
M(4)]8`29>V/)GFQ=DN3?IV%-<0-23WS5^D6N>(7FDXFYK\)<A\N,203]C*XN
MK=N7O.,;&X33DZY<*K6W$^,(XD&I3D=Q$HDD`MGJ9`\5/N]@IBF*$(W[9==M
MW<35BKE`I>6C0XG(H4K3.1R(XC^B)5M.YJ6\V9RZTB9+;2K4A1^E03JE/B",
MC[IQYY_FI>:==_-*O>+;M=,65S%BF+*O+U9C&5V=?3R$D65ESR:[]PO(,62K
M=4/83`@=X;%WWZZ^JME;*IMF4S]-3/+?#RTJ)4`F4A(`2G/IGUQ\_;IW0]N:
MH:>>:2T6T%("23.9F<3*#RKO--N'E;7O*U[IF)JWE9[E*K056=-+'89"OH0[
M>$E'4H5RW-',GIG*KD[KM$#`4`*7IJF]=ET^]*9FF??4P&%E0TI!))$I$F64
MHIM;=#VV'W:AII+I=0$D*)$I$F8EVQ<EYG\LK!S&^G7R;RBM],CJ--Y@Q(=^
MYJD+(KRL=%&'(?\`3K46[]VDW<+I&(Q*J;N(4P"(AJ`=O6-JP<UV;,PXIUNG
M?^H@`G^[U&8&'&43'>[HN[<OW;BXD(6ZWD,OKTX3QQE.//:P,_KT3F_#<K;G
MZ,358O*-!DK/*."*'0CJ^PM$6ZF7RJ213+*D:QZ2AQ*0#&,`;!N.OJ:Y(>7;
M7T4XU/J96$CI44J`&/7'S]0*;17,N.F3(=02<Y`*$SAU?I%N7DM]6;<H6ZR%
M5XB8`IDCCNNK%B8B]Y=>3JTK:VS$@-OS1&K0+N(+",W/A]R)5':RHD$!.!1]
MD(*M'(^F<ITOWVK<35+$RAH"22>&H@SEQD)1+%RYJOH>+5H80:9.`4Y.9'3I
M$I=6)/3'7\;OJW,GFR!"1?*?CQ038YDY)NSFK1B5_/Q<_5V*RJ::DJ6"L+Z<
M:SI&@&$ZB0.6IA('LB(]!ON_(RB%,I5EJW?5I!(2Z$D*,LIITZ>XQ2V\UZHU
M"47.G;].HRFV2".N1G/W1=TH%[JN4*/4,CT:8;3],O=;AK;5IMF(BWE(&?8(
M2<6\3`P`<GCLW!1$I@`Y#")3`!@$-?.E53/T52Y1U22FI:64J!X%)D??$U,/
MM5+**A@A3*TA0/2")@QE^O"/6./^?5"90C#K/D.C4L@&M=MK\"80W*C)2;1L
MX4Z"/X;4ZOO"G0/44=95/15=494[:U]@)CR<>:;^M0!C%X/.^'K&Y*RB,C55
MP[.8")MU)5NT55,([`5(CLZ`J&$?47?KK(>M%S83J=8<">G22/=%B:JG7]*T
MQM@IRG*4Y#`<AP`Q#$$#%,40W`2F#<!*(>O6MQXX1D9Y1^M5A!I"#2$&D(-(
M0:0CS#OJ19/\R\V'-:8"8?RNHXSBQ`5`4_PZTF[V*`?X9?\`.?R^H>OKU]C<
MHTE&R:8G(K</^T?A'S3S&4%[I>'0E(_V1#KOI`H84ZAS0L`D5[7E@Q5$E5$P
M>"88]C;79B%+OW`H0)`!$1Z;"']NH]Y\.'QK>UT)</?I^$=CRC1)JM<XE38[
M@KXQ<>N,S'URI6FPRZB243!5R;F)-1<2E2)'QD8Y>O#JF/L4J96Z)N[?IMJ`
M*=M3KZ&D?\Q2P!VD@#WF)@>6EII;B_I2DD]@$X\9_,\]&VG,>6[/#=GY/9,H
M9`GXGPMO"&,F+;+R+`4^WV?#%HY((;=-M??UO;4S0,-+^M#*`>T)`/OCY`KG
M$NUKKJ/H4XHCL)BWAP=S_<^'GTS_`""RU67+R(MEVRC<Z;CR51$Z*[-:^.ZO
M2WTJP7_F(NQ8-I(Z*I-A3<)@8-A+OJ#-QVNFOW-^EH7P%,-L(6L=(0%+`/:=
M(,^$2O9*Y^T<N*BJ;,GW'E)2>C44HF.P3]L4Z:NXKO\`5M?>7PDK(U;^H(UY
M<$HQP5.<D83\P17G4F+Q<%"I2;YIXA2*F`>U0_<.^VI\>#G@*%.0EX)(1,3`
M,C+#H!SZHB%I39?2JH!+)4-0&9'&1_2+(7*_S3O*6S+PLMO%O$?E\.L8V)E4
M08X@R`@2FH3=1N<>1(T599*<8PJ$W(F>.$=Y'N6$7A5#@?T](DLFR]\6_<"+
MU7W4/,:YNM_/)2#FD))D)3^7##")'NNY=KU=F5;*2WEI83_=J^6:5=)($S/C
MCC"#.+][G\:<DL"9`J4BK'V2H9@QY.Q#IJL9-4KMC:HQ7PA,F/>9%V3N24)Z
M#IG,40$!$-2=>J9FLM%32U`"FG&'$D$88H(]V?LC@;8Z[37%BH;F%H>00>Q0
MBV;]7+9E9!7@]#*J?B'@+Q9U404'M\622C&AE/=]NTNYFPAW>O;;U:@[D6SH
M%Q<'TZT)[IG]XE?FNYJ](@YEM1]Z?A$&?I6H09#S)YB6\,3!7\$7AQW@4@@G
M^9+,H[<1-[1`-XNWL]1]?372\ZW=.T0@?S5*!W3,:/E<C5N`K/!IS_A$:"^H
MRY"V;-WF>9>J4E(.5:O@)G`8KIT6<QBM62:<.QL4Z\20Z)E<R4S-'\10`[E$
MTDP$=BAK:<I[6U;=FL/I`\6I)<4?:4B?8$X#K,:[F'<7*W<KS*B2TQ)"1PR!
M)]I/\2B57D#>2IB#S`*K?N1?)UY87V*:A;@HM2Q[7)5Q7S6Z;:L&LE-RTY.1
MYTI5O&1X/$D$46RB1E%?$$YA*``&EYH<PZ_:S[=ILX3ZYQ&M2U#5H3.20`<"
M3(DSF.B-KL39E'?VW+A<BHTJ%:4I!EJ,IDDC&0F,I8Q9P@OIW/+FQ_EC%^:,
M/57(.*;IBFXPET@U87(%@G8U](0;H'2#:2C[8ZFD3-5Q#M/X?8?8>A@U#CO-
M?=E51/6^O6T]3/-E)!0E)DH2F"F6/1$F-\O]O4U2W5T:7&GFUA6"BH'29XZI
M\1$N/,UKW`2RX-AD?,2ME<@L*5VX,[DVA+#:Y>OH6BP0S)XBS8C%5URE.VEN
MW!^)SM$4U4^_L,H`!MK1;-=W0Q<E*VHA:KDM!3J"0K2DD3,U?*C+,RXRC:;E
M;L+M$G_^@6D4:5A0!)&I0!D)#%6>4HKWV+SU_)2XLQ;FL<2.%+"]*QB*C=F>
M$Q=4,=0+Y3PCE!09^8CIB5>I',;VSJ(`<Q1'4IM<MN8=Z6'K[<2V#B9N+61[
M$D)!]L<&YO;9UK06[71!<L,$)0.'$S5VF44]>7O(&/Y2<B<EYWB,6TW#,=?I
MHTDSQY0VQ6M?@T"E\,H@!"))N))V4/$=*E(0JJHB(%`.FI[L%L79;6S;''W*
ME329%:S-1_HX#'*(@O%P;NE>[6MM(92M4]*<`/XS[8N,_2CXY@<@\/.;]4MS
M=Q(U/(M_@:9/1J;YVS!U#/J/.QLL@DHU4179K.6DF8GBI&*H'00$!`-0#SLK
M'*6_6U^G(2^TTI8,IR(6",\\1QB7^5M,A^TUK3PFTXXE)$^&@S'5@801Y^/$
MOCEPNYOQ^%.,E-<T:D-,/U&>F8AU8INRG5L\R^F5W+PKV>>/WR)%8P&Q?"!0
M2`)1,`!N.I1Y7WR[;@VX:^\.!Q\OK2#I2GY0!(22`,YXQP>^[5;;->O1VU!0
MT&TDB95B=1XD\)1,GZ<ORV.*//D>3CWE%CQW?V6/AHK&HIM;;9JP,6ZE@DG,
MFJ(5R3C3NA<(I)E`51.4H!T`!ZZY[FQN^][8%&+*Z&E.ZRKY4JF!(#Z@<L8W
M'+S;EJOPJ%7-LN)0$Z?F4)$DSR(Z(L8>=/A_%G$;R-\N8(PY!J57&=094*GU
M""5EI&35CV<ODR+D%D#24HX=R+XRCIVL;\50PB!MM]@`-11R]N%=?>9#%SKU
M!=8LK4L@`3DV1D)`82RB0]YTE-:ME.T5&G33HT)2"2936#F22<>DQYM%>@9:
MUS\'5H%H>0G;),1L!"L$]@4>RLL\1CX]F01Z=[ATX(4/[1U]<.N-L-*?=,FF
MTE1Z@)DGN$?.+;:W%I;0)K40`.LD?O%XIE]*S@6O\-9V?N^7\@K\G6>,92[+
MV&*68(T&&M3&OK3@5AM75&XJOX%-='W91PJM[P;<5"B``!=?.*N=5T=W`EJG
M8:_#%X(TF>LI*M.K5/`\9`2B;4\KZ!NSJ<>=6;D&BJ8EH"@F>F6<I\9SBC+(
M,UHYU(1SKM]X8.7C%QV#W)^.S64;+=AO603ICM_$-?2"5I6WK3/2<?=.(3(*
M')3^<'^.V/65\FY%ZAY7W"I.17.Y=!A>)/XJAE#F]V5E)95DENI[7:@R.FF7
MU`4H`'3;7P_O_2=YW$H``]0>^0G[X^J=GA0VQ1!6?@C]3^T,QUQ\=)"[^5_+
MA:D.'F.<9NT_ZH3**=ALA`*J2``Y0$&4?N!DE),2F]LX_P"#ZO:ZAVNW=M>K
M2*VN'^'_`)4Y%76>K]8U%?<"T?!8EKXGH_IB#=(X\YSSBHI9T(UXX:R"@K'L
M]N?J-4WYSC[2J!G(+.W0=-^X"=HAZ!'765=ZM%J'IU$!2?Y$"9'Z`=\:QJDJ
MJD^(![2?X,9E8^#>=*\R/(M(^#L((%,H=K"2G=(%*F41_!2=(-O&,(>@`/OO
MK&8W;:'E:%%;?^D,/=\(]56RJ1B`%=0/QCZX.Y/Y!P?8$JG=_P`WE*@@Y*RD
MX"9\;\VK@"H!3.8PS@HN$RH!N(H#NF<H#V]=AU;=K#17=@U5)H34D3"DY*ZC
MV].<4IJUZF<\-V91.1!X=<.F@9V*LT-&V"#>I2$1+LT7S!X@8#)KMUB@8A@]
M.QB]0,`]2F`0'J&HL>:<IW5,.B3B#(@]4=(A:5I"T&:3';ZLBZ#2$&D(-(0:
M0CRM_/PL(6/S9N72@'`P0]IJT`40`OLA&42LAV^R/M"`J^OKK[3Y8L^'L6AX
M%2%J[UJCY=WXX%[JJ^@+`[D")<>2!YRF!?+`QGFJH94Q9DB]SN3;M"V&/D:2
MY@TV;2*BH?\`+P9/4I9PW4]Y!R<YP,3<!*;8?[-'S&V!<]Y5E,_1/---LME)
M"PJ9),YB7"4LXV^RMX46V:9YFJ:<<6ZL&:98`"7'KC=_F<?4Q7/EGB"S\?N+
M^,)["-)O;%:$OM[MDQ'R%ZF:XZ(=&1K\$TAP48P;*72.!%W`JF<^'N0``#".
MM;L_D^Q8[@BZ7EY-14M&:$(!T!7W*GB=/1*4\8S]R<R7;I2*H+:T6F7!)2B9
MJ(Z,,`#QQG+#"<5KL"X)R=R5RU2,'X:JLE<+_>YEI"PT1%H'6%`BZI".91^H
M`>$PB8MN85G"ZHE323((B.I<NEQHK/0.7"O<2W3-IF3^@'6<@(CFAH:JYUB*
M2E2I;[A``';B3T`9D\!'H2>8IY<LEB_R")+B1BAJ>S6+CY2Z3?I$D8@<%K7-
M5:>"QY-EVK<!,H8JWYO)OB$ZF\)$"AU``U\L[3W8FLYG"]UITM53BVQ,X)"A
M)M)[))':8GS<&WE4NQ#:Z8:G*=*5F7\Q2J:S[R>R//$Q!=HG'.4<>W^>J,/D
M"!J%MAI^;H\^GXD/:HE@\34DH&0)N402?M.]/K_*<0$?1KZKKZ=RKHGJ9EPM
M.N-E*5IP4E1$@H1\_4C[=+5(>=0EQ"5`E)R4!B1V'*+U6,N=GTSU]HD;;+)B
M##.-9]:/0<3=&MF(98)V(D3)=SJ.049,5FDP5!4!*59N82*!L(;;[:^;*S;?
M."EJ"PS45#S0,@M+HD1TR)F.PQ-]+>N6[[(>6PTVX1BDMF8/1,"1[1&YN&^=
M_(^YC\KHC`G%/AM4[39(."DLBK9+<8I3JM=K9*DXCU6KM$DT9&3=N#RKI$B)
MDTM@/U'IK`O]NYC[?LBKG?+@XAI2@CPPYJ4K4#/+`"4YXQF6BMV3>+JFAM=&
MA;@25Z]&D#3+IQS(EA"C_JZ+"BMR=XLU!$2E+#8.E944"[]J8/[K,M4O8`-@
M#PVH`&P^K7<\BFI66M?/\U0!W($<IS9<_P#TJ9H<&#[U'X1K_P"DMBA=\Y\Y
M2HE3,6*X[K!N8?Q2G>W*&0W2+OUW+N`_V:R>>*M&W*9.("JK]$JCQY4C5>'?
MZK*O>I(_:(1_428#M6%O-#S?8IE@[2KN<2P&5:7*+$,#:28.X..@)9NW7#=-
M16,G(98BA`'N(4R8B`=P:Z3E3=&;CLRF9;(\6GU-+'00HD3'6E0D?A&CY@T#
MM'N=]Q8/AO26D](D`>XB),^1;YX&._+FIE\P#R$J%HFL46RVC>*U<*:@G)2E
M0FG,>VCY>.D(,PE<R,5(%9)*I&0$5$U>_<.T=:?F3RXJ]V/M7*UN(36MMZ%)
M69!0F2)*X*$SGA*4;+8N]*?;[*Z"N0HTJUZPI.:21C,<09#(SGPBSIQK^H2X
ML<P>4F*N+O'C'65+3-9(>2WOMQL$<TJD'5XF$C5I1_(NF$BH,K(#X*(E*1(H
M;#Z1VU#=WY5WFPV5^]75UEM#21)"9J4HJ,@)C`8],2;;M^VV[7)JVT#;JU.'
M%1D`D2)GG,Y'**>OU$V:<HY1\T+.U.ODE*_TKAMS6J5C2M.E5@BXBO*52%G5
M9-@S$0;>]3LG+KJJN"@)E"@4HCL0`">^5-NHJ/9E-44R4^-4!2W%#,JU%,B>
M@``2X8],1#S!KJJIW-4,/%7A,R2D="=(/O)G/LZ(V=Y,?"/RO,_T;(F9.?\`
MR5@J@]HUG-%QF%7]U1Q\16`;1C.1+<IF6,8)"9C9%TNLW(U;!L`MC=Q@$0`<
M+F%N'>=KJ6K=MBC4XEU$RZ$ESYID:`,@0)&9Z8R-FV?;-<PY57VI2A2%2#94
M$F4@=4\Y3F))A8?F+RO&&4YAY>_^'$7!Q7'&+D6,'C@E<0?H1$A'P[(C1Q,M
M1DSG>N`E'13*BL<=U=^[8-]=EM-%Y186#N`J-U4DER<IB9R,L!+*7".;W$NV
M+NSOX@`4(5),IX@`8XXG&9BZ9])?#&:<$LRS9DS%+,\AIAL54>WM4_**S"%,
M!1#VMTQ?==^G7IKY[YXN%>Y*=HY)I1[U'X1,O*M&FRO+Z7Q[D)^,5Q_J6)!Z
M\\V/,;=R!BHQ=)Q,SC]P,`':JX^@'YS%$P;;>^.U`Z=-P_CJ6>4"$IV13J&:
MG'2?]<C]!$<\R%*.ZG@<DH;D>K0/B8V%Y!/FQ<>?+6=<AHCD+$W,\-E%&K2U
M?G*?$'GE$9&O)/V[B+?QR(E73(Z2<$,FL&Y"CN!O4.L/F?LBZ;N12.VI3?B,
ME04E1E@98@^S$1E["W30;?+[=<%Z'0G21CB)X'MGA#_//PY.5WD'Y(5<S'5(
MB<KM=S]=\42U=B;&DFUG$8IO;S2*`R#9(QR)*.FT0*H$WW`APWZZC#EE9W;5
MS%70/*0MVF:<"BG$3TRP["8[K?5S;N&RDUC25);J%H(!SEJGCW12K\M6L-KG
MY@7#:N/$DUVK_D5BQ1RDIMV*-X^U1\BL0=^FYDV@[?Q'7T-NZH4QM>X.@R4*
M1SWI(B&MMLAZ_P!&V1,&H1[E`_M'K,YX>)16"\SR!@*"4=B?(CPY1'M*!&=/
MF%A`1#T%[$_]`:^'[8DKN5.GB7VQWJ$?5=>0FA>)R#2_]TQXS4\Z*^EIU\0N
MP/9.6>$*`[[`Y>N5RE`WK[?$VWU^@#8TM)3PTR]T?'JU!3\S]T>N!Y;B\+1_
M+IX6)SDHP@FG_P`=\3`"\T^:1J0O)6K1[XK<%72J*0JJ*N3=A0'N$/\`3KX9
MW>EVJW9<?""E*]4YD"<`HB>'1*/JW;A;8V[1:R$I].C,RQ('3UQ(CD3E8F)<
M4SMJ:*IFEW22<77``Q3%4E)$!(@N40$0,1JEW*[AN&Y0_CK76.W_`)*XHIUX
M-#%78.'MRC:UE0&&"L'YC@.V%R</^/Y<LV*0R;?TE)*LQ$D=1!N[[A)9K$<X
MKN%71A,`JLF*@[J%]!CB!?1KMMS7G\>RF@HS)]2<2/Y4\/:>$:BW4HJ%>.[B
M@'#K/3$H<S\V:?C*06J%!A6UNEXH19NUDW`,:Y%KH?AF8D4;IF.Y50VV,"0=
MA!*(;ZT%KVI4UZ!4UBBVVK$<5'KD>GKC-J;FVP=#0U'CT"-14WS$GQI1%"^4
M5FC$K*E*J_KKY=5TR(<P@*IVCM(I7)$BCOL0>\P`.W76RJME)#<Z1T^*."@)
M'VC*,9N\*F/%0-'$B-S\@</4KD?C=/)V.%6+NT-(X\E$2S$I2&GV2"1E7$))
M$#M'WLH;@3O#Q$U`V'H.M79;G56.N-!7`BG)D0<=)X*'5V<(R:NG;K&O'9Q6
M!W]1C3G`3+3M%],8:G5E"D['4U6$W(B"C1TU$I9B(*4W4NZ8"L!/004C;=3:
MV>\K<@H1<V1\Q^54N@_2K]O:(Q[4^0HTZ^T?O#2=<!&\@TA!I"#2$&D(JE\M
M?IA*YRMY)YCY&37+RQUR3RY<7-K<P*.,6$DE#@LT:,4(\C]2VME'9&[=F4H'
M%,F_\-3;8^<CEDM%/:6Z%*VV&].KQ")\9RTX=D1;=N6;=UN+MP<JU)+J]4M`
M,O;JB.__`.0"D?\`W5M'_M)&^O\`[Z:V_P#GR_\`^.1EYI_L1K?\HV1E6J_[
M8_M1EU+^D,P>QF&[B_\`+;)-D@TE4C.(NN46#K#]R@4X"LB26=S4\FU,H7H!
M_=E.T>NPZQ:GGO<5H(I*%E#IR*EJ4!V@!,^\1[L<IJ-"]515N*;Z`A(]Y)_2
M+"G"7RR^''E^PCIAQQQ8UAK#*(%;SV1K*Z-9LBSR0%(4R+RR/$R&9M%1(!CM
MV*31L<P;F3$0#:+-Q;PO^Z'`J[/%3*3\K:1I;3V)&9ZR2>N._LNV[1842M[0
M#I$BM7S+([>`ZA(1/-PV;NT%FKI%)RV<HJMW#9=,BR#A!8ADUD5T5"F36253
M,)3%,`E,`B`AKF$DI(*2009SXQO2`1I.1$5BN;/TO'$KD7<)[(^`KW8.,-JL
M;MU*3%=C(="XXU<2CI7QW#N,KCF0B)"O%<*&,91)!VHW`QOPTTPZ:F/;G.6^
M6EA-)<VTUC*!(*)T.`<)JD0J76)]),1K>>6=JN#QJ:!9IG%&93+4B?4)@@=0
M,H6./T@V8OS#L#F/CK\L\40]Y''EA]_\`?0<6?YB*'B_]'QMO[==C_GO;BB8
MM[VN7F)EWRG[HYG_`"DJ]6-6UH_T5?I.'=>45Y&%>\KS(]\R^]SFZS+>+M1@
MH94R4M"IPT%%JS,?-/5VG=-S+QTY=+1B)!$12`"%'H/=TCG??,IW>=&U0II@
MQ3-N:_KUE1D4C@D2D3':[3V0WMFI76%[Q7UHTX)T@"8.&).8CK_-0\B"$\SK
M/M8SC.<C9K%@U?';#'[.M,*&RLB)D&<K(RQW_OZ]AB3D.X7D3`)/#';;^;U:
MOV5S+7LZV+MK=('M;I65%93F`)2TGHBW=&QT;EKDUBZ@M!+83IT@Y$F<YCIC
M)_*<\C^K^5OE7)V48K.TKEY[D6AM*,$?)4MK5R0J+:=:39WR3AM/2PN3K"U\
M(2"4H``[[Z\M\<QWMYT+-"NF#"&G-<PLJG\I$OI'3./7:NRF]L5;M4A\NEQO
M1(ITRQ!GF>B)V\^O+CXS^8UC!OCKD#6W1I&!4=O:)D.M.$HN\464<H"F=>(D
MSH.$UXYP8"BZ8N"*-W`$`=BG`IR\QMC=MWVE6FKM:QH4)+;5,H6.L3SZ",1&
M\ONW;=N&F%/7)^9)^58P4D]6>!X@X&*L5V^D$NQ)QT..>9-9<UQ1=4S,EQQO
M)L9EJW[_`,%)<T/,R31VJ4G0QP%(!'T%U-=-SXIBV!5V]P.@8Z'`1/JF!$7O
M\I7BL^GJT%N>&I!!EUR)'Z0S;RIOIZ&?EU<C(_DQ;N0Z>6K;#5:Q5J$K,50R
MUZ$CSVA@,<_D5)-[-R+URX00,()=J"74>HZX[>_-56Z[2JT4]+X#*EI*E%<R
M0DS``"0.W$QTVUM@)V_<!<G7PZZE!`2$R`*A(F9)X98")%>:IY%6!/,MGH_*
MR%NDL)9^BXA&`6R!#Q*,]#6N&9]YHUE;ZVH]CA=N(PRIRH.T'"2Q4SB4X*`!
M.W4[)YE7/:#9HO#34VLJU:"9%).>E4C*?$$2GT1G[HV/0[D<%4%EFO"9:@)A
M0&04)C+I!!A&$'](%DA67*2S<S*8V@2K%$SB%QG,OI91N"OM@5H^FX]HBJ=$
M.@^,8"F'U[=9)<Y\4GAS:M[A=Z%.)D#VZ2?='$HY2U.OYZML(ZD$GWJ$;WEO
MI!<8+/5#0?,JZL8[PT`3;R&,(B0=%5*F`.#G=)6IH0Q%%0$2E`FY0Z"(^G6L
M1SXK`B3MO;*ND.$?\)C.7RDIBJ:*Q8$OL'M_F'Z18`\K3RZ83RRN.LO@*&R5
M(Y5),Y'L&0G%GDH)"N*$/.1\,P)&)1C>0DR%3:%B>[Q!6$3BIZ`VZQ=O7=CF
M\;JFZ+9#.EE+82"59$F<Y#.?1PCO=LV!.VZ`T"7"[-PJG()S``$IGHQB''FU
M^1'BOS,[=`9C@LD/<)YSA(%&JR-E)!%LM9N5?8K*KQ;:P0@/HQPA*1AESIIO
M$5C&%$2D,F8"%UT&Q>9=;L]E=O=9%1;5JU!,]*D*XE)Q$CT2SXQI]U['I=R/
M)K$N%FM2D`F4PH#*>(,Q/.>6!!A)U>^D"R0XD/#M_,ZG,881*"BM<QK,24DH
MB)ME2II24U&-D5!3'V3"H<`-Z0U(CW/FE"/[B@<*_P"LXD#W`_I..-9Y2U`<
M!=JVPD'@A1]VH189YW>4?6>9_#+!/#2-R])XHJF$'5/60GV-5:V!S8TJA5%Z
MXBD[CEI:-39F>N5Q>',54VRGL@`AUU%>VM]/6#<%3N!;`?>J=?RE6G3J5JSD
M9RRCOKYM-J\69BSI=+33!3B$SGI21B)C///.%L<1_I@:?Q4Y+8:Y%,^5]AN+
MG$-T87%&L.\91T:A-*,$UB$9*2!+4\,T*<5=^\$CB&W0-==?><CUZM%1:C0I
M;#[91J\0F4^,M(CG+3RS:M=Q9N`JU++*PK3H`G+KU19FS'C]3+&)LEXP3FEJ
MV;(=%M5*_/T&I7J\.6S0SN'4D4FAED".3M4W8G`@G(!A#81#4.T%7Z*N9K"G
M5X3J%RRGI(,I]<HDFLIS5TCE+,I+J%)GT3$IYQ4&/]()0T$/\QS=LJ8=H%,L
MKB>*3`QMO:-N:[`!1,/]NIY//BJ)^2W)_P"Z?[$1,>4K`Q-:9_\`MB7^]E%A
M+*7EV0^4>*/'SC.&3WC1K@6M4NO,+.>";2#2SA4*ZR@$Y%]"A()I-':AF)5R
M"18PD`3I;]JAC!%E%NQRCO=5>"P"JJ6M13J(*=2B9`RQ&,LN@YB.]JMNIJK5
M3VWQ3_ATI`40#JTB4Y<#QZLN,:NYI)*U..PA@Z-E'TPWJ%1:)^]OE!.]E'8`
MW@63A^(";O<*%8@IUWV$X[>G6ZVJ4OJJKHM(0IQSV`?49=\75Z/!;9I4DD-H
M&/$\)GAPB2669XO&SBQ7ZQ7%?<[!,1C.`8.4P`BY7TD@#R<D0'?N%T@BJ?8V
MP]=M:*W,"^;A6\\-3"5%1GT#`#VQGOK-)0A"?K(EWYF(V<5.)T=E&+-D3(QW
MHU=9PLC"PR"ZC9><504$KE^]=["J1@1;<A0(('4.!A[@VZ[[<6XG+<YZ*B`]
M0!\Q(GI'``=/&,.AH$OCQWOHRET]9B3>4^$6++-6GJV-F(56T,VZIHU1J_<O
M8N1703,(,9!)VNX$@KF*!04(<O88=Q`0UH+?NNX,5`%<?$IR<01(B?$2Z.CC
M&8_;6%H)8^5?;@>V(Y\'<B35*R5-X:L1E6[&8._]WCW(C_U;9XH>UPFF!MQ(
M#]$@E$H=#&`#:WN[:%JKH$W1@`K0!C]R#EW&,.V/*:?53+R,^\1B>5(TV#>8
M49.1@"SC9&QP]I2*3\-,L?/N3-9IMN'04U5`7W#^"FWJUD6YS\MME33F*TH4
MCVI$TGV8194)--<`L9$S]ASASY3`8`$/0(`(?W#L(#_'47'##C'1Q\@=-A5\
M`KA`5^OX(+)BKT]/X8&[^G]VJE*].J1ET\(1]]4A!I"-59'L4Q!&C?RNR5^"
M!<5?%+-)`H9?M*`AX&X?[H^G6QH:=IZ8<;6N7V_O'@\LHE)24]L:N^8=OW_X
MBT+X4GV:V7H*7R'N^/#Q7/,;@^8EO_<6A?"D^S3T--Y#W>8>*YYC<'S#M_[B
MT+X4GV:>@I?(>[S#Q7/,;@^8EO\`W%H7PI/LT]#2^0]WF'BN>8W!\Q+?^XM"
M^%)]FGH:;R'N\P\5SS&X/F';_P!Q:%\*3[-/04OD/=_]$/%<\QN#YAV_]Q:%
M\*3[-/0TOD/=YAXKGWMP?,.W_N+0OA2?9IZ"E\A[O,/&<X.-P?,.W_N+0OA2
M=?\`5IZ&E\A[O,/%<\QN#YB6_P#<2A?"D^S5/04OD/=\/&<^]OWP?,.W_N+0
MMOX>ZD^S5?0TOD/=YAXKGF-P?,.W_N+0OA"?9IZ"E\A[OAXKGWMP?,.W_N+0
MOA"?9IZ"E\AZ?:8IXKOF-]T`9#MP?^HE!^%('_)IZ"E\A[O,5\9SS&_?'/S$
MM^W_`!$H7]_NI/1_#T>O5/04LY^`]WP\5WS&XX^8=O\`W$H7PI/LT]!2^0]W
MF'BN9:VX/F';_P!Q:%\(G]FJ^AI?(>[S#Q7/,;@^8=O_`'%H7PI/LT]!2^0]
MWP\9SS&_?!\P[?\`N+0OA2?9IZ"E\A[O,/&<^]OWP?,2W_N+0OA2?9JGH*7/
MP'N\P\5SS&X/F);_`-Q:%\*3[-5]!2^0]WF!=<\QN`,AV_</_,2A?"DZ_P"K
M?T:>AI1_T'N^'C.9EQN-&9!QVGE"2/)6[++!\.Q2MV"$HNTBV:8>@K9B@!$$
M^H]3;"<P^D=;>BK#;D>'34J@>D@$GVG.,1U@/JU..3/4<![([/&]3<8J<*FJ
MF6(LC-P7L7B9*07D(HXB&Q%2M''>1%8@_P`IR;&]6^VO.NJ$W$`5-,K4.($C
MWB+F&O3S+;@T^Z.@R%BN&R==8Z_6?(E>4FHL(PK5-FL"+`"1;@CIN51MX1@.
M4ZI`[P$?:W'7M15[M!2FB88<\(DYYXB1QBQYA#[@<=<&H2RRPCNLO4AOFUO"
MM;ED:M%;5]1RJQ1AU08E!1VD5%0Z@`F8#"5(NQ?0`!KQMM0JU*4JFIW-2Y3*
ML<NB/2I;34R#BTR&4L/C&2BVD$L=HXPB\G5F#K[>*2A4W$08&DLFS(8#J@1\
M1/O36=^UXIR@`F[S>C?7A\AK3<'*=Q;I.KYL1/+*+I?W/@!Q(1*4QAA^L:&X
MM2T]COD;8<3M;,M:*H_8OU#'][5>-?>FI6SIK((BJ)@3<ID5,DJ(`'?N&_H#
M6VW`TS6V1NXJ;"*E)'"6!F".SB.B,6A4MFM-/JU(,^OVQAN3VQ*ESFAW$0`)
MF=6^K3"Q$0[>YQ*D$7A3%+TV/ZP]?KUDV]7J=IJ#N,FEI'_IRCS>DW<]2?N!
M[XR#S"D$T<DX[>)E[5UZ\N114-@W*UETA1W'T@"8KB/^G7CLLE5`\@Y!S]4Q
M?=P0\A0SE^\2DD[1;;)6"0RN5*S$IOXYJ1PYB?\`)RA$S(IBHD1X0OBH'/Z#
MB00-U$-_3K0MTU*S4%P4[BU!1P(FF<\Y91G+*UH""ZD"41\2X^U5N_"60R<W
M1E"J`J603G7Q7@*[[^*#@#`?O$?7OZ=;HWJH4WX9ICHZ-(EW2C#%$T%:@X-0
MZS$F(JZ6Z(C6<9\TJA(^Y(E0!Y))%<OERI@/89RN)"F65``ZG'J/KW'6C=HZ
M9QPK-,Z)XR!D/9&>E;B0$EQ!EWQNW\_E?ES^>_U!!?FGNW?^>^&'Y+W^_>#W
M^'MMV^'['H_GUIO"9]=X?AK\*?T?S9?'&,C6?!US$^GAG&1V&E52V"W&R0,?
M,BU[O=Q?(^**/>&QNSJ&W<&O!BKJ::?@+4B?1%ZVVU_6`8B'D;,7`+$=U1QQ
MDK(6$:;>U@:B%4F9QBA-(^_&*1F#QF1911@9T)P\,%_#$X"`ATZZR/RMQ\Y?
M?%GI&,]`B2:>',4*ID52H]=.FH0JB9RM=RG(<H&(<H@?8Q3%'<!T_*W'SE]\
M4]+3_8(_?R8Q7^A:_P#"??T_*W'SE]\/2T_V"#Y,8K_0M?\`A/OZ?E;CYR^^
M'I:?[!!\F,5_H6O_``GW]/RMQ\Y??#TM/]@@^3&*_P!"U_X3[^GY6X^<OOAZ
M6G^P0!AG%0[@%&KPB'I`&GH_O]OII^5N/G+[X>EI_L$'R8Q7^A:_\)]_3\K<
M?.7WP]+3_8(/DQBO]"U_X3[^GY6X^<OOAZ6G^P0?)C%?Z%K_`,)]_3\K<?.7
MWP]+3_8(/DQBO]"U_P"$^_I^5N/G+[X>EI_L$'R8Q7^A:_\`"??T_*W'SE]\
M/2T_V"#Y,8K_`$+7_A/OZ?E;CYR^^'I:?[!!\F,5_H6O_"??T_*W'SE]\/2T
M_P!@@^3&*_T+7_A/OZ?E;CYR^^'I:?[!!\F,5_H6O_"??T_*W'SE]\/2T_V"
M#Y,8K_0M?^$^_I^5N/G+[X>EI_L$8P:F\?26]+'YXFC%O"\">THU,RC<)]2N
M)O?RT\X2,%;WHT61_P#@BL!>SQ/9WWT_*W'SE]\/2T_V",G^3&*_T+7_`(3[
M^GY6X^<OOAZ6G^P0?)C%?Z%K_P`']_3\K<?.7WP]+3_8(/DQBO\`0M?^$^_I
M^5N/G+[X>EI_L$<_)C%8?]A:_P#"??T_+7'SE]\/2T_V"(QY7X2Q-SECS=#O
M\]CA1<2BZAV;=&2@SF`!`RK1!P8JK`1#;V"")1'KTUOK=NQVE:\*K90^."B2
M%>WI[8PG[8'%:F5J03PS']$=WB#AM6L?N%).Z6N9R=)G2,DBA-(HLX1F!P[3
M'3C6QA!POVA[)U!W+N.P:\;ENBIK4^'3-H81.<TXJ/M.7LBM-;4,F;JBXKKR
M[HA]S(@6F-<Q4]S`M2P]8D(J*DUXQF91&.7-'RPHR**B`'[3^.W1_$#<-RCK
MIML/KK[8Z'B5/I41,XG$8=T8%Q0&:E)3@B4_?B(VAS.Q_%1>-*3D+'L:C`,_
M>T0FE(,3MTUF<VR3/'J*BF<Q3@F[,!0$?1OK7[7K77*YZBK%%:I?+JX:3C[H
M][BPD,)>:&D=6&<9S@2N8HY`8/+#+L&<1=H]D6%L$I$&!O86#UNKW,)Q`YU#
M'4(\23+W&,`D4,!RCMK$O%1<K-=O$"BNE*M24GZ2#F#V&/:E13U=+H.#@$B>
M,;)PYQNI/')6RY!FK2ZG9(L<Z*O/S)&[-")AR"#EV"92B('<.A1+WG$=S=H%
M*'76!<[[57L(HFFPAO4/E3,S5P[H]:>C9HM3I,S+,\!$%\9.UL]<Q4;:W2.>
M);6)S92=^YBI0<%N6/35-U`@+;AVATW$VVNNKP+/MGTRB/$+83UZE9]T:MA7
MJ[CK_EG/V#*,AYN/_P"KL_5&GL3`LI'QL+%&(7VNU]-RACJ(B`;B!O!!,1#T
M[#KQVHGTUF=J5_22H^Q(B^YD.U0;SD)>TD0PZQ\=<6V2M+P']/(P2R[5)-*9
M@3&82S)=(@=CANX`QMQ`P>T4P"4P;@.N+8OEQ8?#VO6`?I5BD]4HVRZ-A:-(
M&DRS&<1(;^7Q*EFRJN<]VY:OE6[_`'-.)CTI(Z`=?=Q>>(*9!'T=X`(AZ=M]
M=$=YH\*2:-OQI9ZC*?3*-=^'5.1>5HGT"9B94'@/%,'$L8DE2CY(&3<B`OY8
M#/I)X8O4R[UVH8#++*&'<1V`/5Z`US+MYN3KA<\529G).`'8(V::2G2D)T@R
MXG.-@?TA6?Z?_I3\D8?TYV>'^3^%_D>SQ_>>WPM_1[Q[?I_FUA^JJ/']3K/C
M_=QRE^F$>WAHT>'(:.B,CUCQ?")Z;%5'@1R0S+5>5^+ZE:\)<O\`.[J_8RY@
MS=7BK,2-N5Q:1$>CA3D))RC%RM3640]8D;U626/^4+)JB@8R*W0Z/3ZDX<(>
MFD"0)I@B"8(@F0$O#`H)>$!2^&5+L]@$^W;8`Z;:1YPL7#O-6T5:B<ZAY.NZ
M^E=.%N2;X5^O"1BU=;6C%$A&#;<*RZ,8X?2*P2-I@7*+,5"'%-9Y_*4HF[01
M=*<I<8E/P^L^:[SQRQA?N0B,+'Y3O\$-WF8&`BU8EA58NTN5IJK591LN]?+J
M2D)5W;1%ZH<Q3&>%5]@FVVD4,IX91"&]9JY"6[GW:^-+[.\-Q4K<75J5:^.\
M<^Q>RN9>3[-9LLYR4LE;9RR0D<G)4^01]R/`,@"1(W,5Z)S)F[01=(!,QB8;
M@0JH(%(=4#+@D!#+`3M*97LV,J"7>;M*)^O;W#MZ-](LA-_EW0_*">SOS0N5
MYY,M[MC>N<O<FTE6@.\3N(XTDE"52LDAW%8LCO(<H:G1,6>33*=@@Q<).%&Y
MC]Y!5$"H]%2TB0S$3.Y[\IPX;<7\@9P90J%EM$:O6:I0ZVY+('9S5\OMFBJ=
M5D)!.);/996*9R<R1T\(U15=':MU"I%,H)0TBU*2HR$*^IW/'-=3R;Q]28YD
MLO*0F5\GUB@9GQLGP^RIB-ECR*MC)X+B_8]MLFV7:H05*EVZ:+IM*J+&=MUP
M5!5(Q>S58N*>J4/FM\LK`U*T3B"B22T-79N5267*!T$E8Z,<NR*+$$Y.](AT
M0$P=P;@'I#5(\XKMH\L_,J3\NRL^99,93PFD]BXF-LI.-#+%;UM5\D4MQD`*
ML0)?(;FX*S-9N-FC5BK,S-&CAFT,*8&!;O-V5CT(3JD(F%.9(YP8"S=P[E\K
MYCQKD>G\J<H?*R_X9A,7KUIOB]W+4N9ML3)X\NY;1*R=A3KSB'%H]-)-4@>D
M."I2HB/8"*``@PVZ?<RC*!FGD&Q3E)MI$R+F'C%5@;)24J@S65CV"KC8003>
M.RD3,?;V0-OJD6#.%6^6]F#._(Z/?90RMR,AG5TA9*R5?./$8N(F=/EL%75M
M)OFT97!DGEI<VOW=DV;IJ(2;EHJUG6Y@70\(H[`B]4AA*&TZ19!I"#2$*H!-
M!_YT+ER)4BN*]Y?$.S(8"D.LJE.9OLSD_>?8%$"IFCP``Z@???U:1?+^[GUQ
M)#S!LXWKC9PPY"YSQD6&4R#C>AJSU/0L+,[^&=SQI6,CV#*0:D=,CJHOEGH(
M]%2"4QP-UVV%%$B:I&%]YUR-YCO'SB^UYQVO/&)9>1K%;H]YR)Q:88;<MZ*I
M6YM>%3GJI7LDFN2UL+:V3.0,9*048BW.Z`2>`"8`<45`!.GC#O8QZ62C8^1*
MF=('[)J]*DI_.D5V@1<$C]`W,0#[#_=I%AP,H5#0LC<L^;N0^0$QA[--=XUX
M"PIENVX-H3QKC%GDF[Y3NF.7'Y5=KG/.YFR0D9#TQ"Q][5E'MT1<N4D14.X2
M$P!H<HOP3F,8:95&-@C*U!1ULG6MHLK&+9M9VQL8;^GFDW*(HE3>2;>""0E0
MBDGBP"<$/>5P3WV[S;;Z19'?_P"S_9Z](1`?GYCM2QXWB;LR0%5W2'YP?^&4
M3&&%EA20654VW'PF;A,H_P!Z@ZZ_9M:&*]5,HR#J<.B8^,:JZLE;(<&:#CV1
M\>+]KK>?<$R>';@H#F3@8PT'()',472\.J8PQ$PT,?N$RS,X`43!_(<I0WZZ
MNO\`35%GNZ;G38(6K4.@*XI/48I0N)JJ3P'?K`E\#$#KGC[,W%F[JO8EW,1:
M'BJ%A[;#D4/%S+`3@*2+S9-5KX_:8OBMUBB)3=0Z;&'KZ6MM>X*30X$J,OF0
MK-)ZN,N@B-6XU44+LQ,#@>$=/8LMYXSF=E4G\Q8+,5RJD1*O1#'W=NZ7W`H'
M=MV"*0."E,8!$5A%,OIV#;7JS;K1:0:A"4-R_F)F>\G],8HI^IJCX:BH]0$,
MKP!B*(XO8SL>0+^X:(V9Y&&D)U4%"&)%,&Y/&:5]HJ'19PJOMW]N_<J.P=`U
MPEYN3NX*]NBHP33A4A_6)S41T?M&XHZ=-$R77<'")GX1#GCM'2F?.4#O(,N@
MH=A&2;RZR'BAWIMBME"HUUAN;<H'26\`HD]9"&'747MQNT6`4;1`6I(;'7/Z
MC[<8U](/55Q>.0,_A#H]1;'1P:0@TA!I".!W$!`!V$0'8>@[#_'8>G32$*)Y
M-X.\P_E-C3*?%RY(\3(3$.5U9.JRN88]K?).Z0^-I"0$Q7$5C>4>K1`9&91A
M2@W?C)`T1>%!8C<O:4`1>DI2=7&&I52`:4NI5RL(O73QE5*[$02<E)K`H\<M
M82.;L"O9!R80*=PJDV\14X[`)A$=(LA&'*S!$?R"\U;&&,:);T1IUKPS4\A<
MY:5')`[:3%-P_>59G!;&??(.A(P?W*Q+"S.V,0JJT8R(IU3$!U6/0&2,?9#\
MBD*0I2$*!2$`"D(4`*4A2@`%*4`V`"@`;``>K5(\X4WS)XW<P.6ZP8B>0_'*
MH8PB,N4'(>/\^LW=S=YJQHSHUIAK,#ZKUTXDCFE\E6L:XC#ODI!)H#-\J!FQ
MP$0%%X(&.,-?;)'0;MT5%U'!T4$DCN%=O$7,F0I#+*;=/$5,7N'^T=(LA=?$
M[`?)#CIF;D%!2ORNL_'O+F:[YG.%N2,G86N5(V2N\9$I#4)&O*(*0"S6,D(H
M.UZ1P43H&$!2`VP@BXD$#JC?7,7C<CRMP':L1HVIS0;0O)52Y8\R`S8HR;JB
MY)QY:(B[46SECESD2D&L?8X)#WEN)B>\-3*)]P";<$4!D9QKG"3WS!QLM6A\
M\5'BVSJ46V5;W"[X^F+Z\L5J5;MO!:OJ_5Y0C=G5E7[DH++$<.Y$B8&$A?4;
M2*G3PG$MLAP+^U4"\U>*70:2EDI]F@8UTZ*8[5L_F(5[',W#DI?:,@BX<E,<
M`ZB4!TBT80MFU\%,G3WE;4;@\UN%3;9*KE%Q!5Y6VF:/OZ4=O*+<ZQ8["LW:
M$,#XK639PZZ:0".X&4#?IOI%VKYIQ)#/W'FWY8RWPUNL--0C"M\>,GSU^N4;
M($>B^G".:%(5>%2A!;G*@1PTD)`RI_&`2^'T#KI%`9`]<2EM@VDM9G1HX08V
M\(QV:N%LQ'JE?-,`D;W(LP2-7:OQ8&6``5\%0A^WT#OI%(6QAOC7R5F^9;#E
M_G*)PEB.1@L/3F*9RMX+?V6>?YL&5D8F2BI;(\W.H1:0QE'5BU3P[3W=PY0.
M\.!G)B>R*+IC3ISB4G%#(N?<K5"\7;.V.X?%B;[*M\CL24]J1^6S%Q!!3;B'
MIEAO@O'[U`EHMC5D:1,BW*BD@W<)$$@'`VD4,N$2ETBD&D(A?`\;[5'<]<A\
MJWDQ!+5"T\<\?8;AH--NX"PL9>K7*X6:5?.7!A%L,<\2L*)2%+[7<F._JTB[
M5\NGKCN>=."+ER:XL93P;0IJ&KUEOS:N,FDM8$G"\2V;Q=O@)]^#I)K^.?QF
M<4<A`+M[9@]6D$G2J<=)S6XX7#DCQ'MW'RFST/`6&S,*7%#,2Y7OY6FR@IV$
M?2Y3%8G(YW=,(Y0B0`.W<8.[IOI%`9&<3+:MR-6S=L3?L;H(H$W'_=13*F7_
M`%%TBD*QK/'OF3Q1O^:4.+)L'Y.PCFW*%JS2SI^7Y*U4^RXBOM]>!(W2/A9B
MM)2C"U4B1EQ.];M56S1XW.J9/W@Q=A!%Q((ZXGKD4N<U<0O@Q>MCIGG(\)&"
MP5MC6<=XZ0L0@T&7\=LP>MYM6*)NL"``L"@^SW"([Z1;&U&!7I6+(LD=`\B#
M-N5^HT(=-J=Z")`=G;)J&4.F@9?N$A3&,(%V`1'2$?SS4-'6")DH.6;)NXV6
M9N&#YLH4#$6;N4S)J%V'<`,`#N4?24P`(=0UZ-.K8<2ZT9+201[(M6D+24*^
MDPCF^U'(G$3+R$M77#E*.]Y6<5>9,F)H^<AU!_'AY$H"*8J))F\-5(P[B``<
M/XZE>CJ:+<EM+3TBJ4EIXI/!0^,HYIUMVWOZD_1/`\)=$,#QUS/PYD.)187H
M[>H32B8)OXR;;'?0CE78`,+)Z"*Q3)*#U`JQ"B4!`-S>G7&UNU[G1.ERCFXU
MP*3)0[1\(VK-QIW4Z7?E5UY1FLAR#XT8Y8KOHZP5A-50#'!C5(PBK]Z?VA["
M%:-DDNXQ@_WU"!OK%;LM]KE!M:')#BLX#OG[H]%5E$R,%)]D+8SMR)N?(^>C
M:=6(IXPK!I)).$K34QEY*=D!.)&SV5,D`%,<G=N1(`\-'TCN/M:[JT62EL3*
MJE]054Z?F6<DCB!V]YC4556NL6&T`A'`<3_'NAG'&3!Z.$Z`E'O@26ML\9*3
MM#I,"B";@4@!"+14+N)V\<0PAOZ#*&,/HVUP-^NYNM9J3_\`'1,('5//V_I&
MYHJ84S4C_P`PY_#V1)'6DC,@TA!I"#2$&D(-(1_%)QK&9C9"(DVR;R-E6+N-
MD&BO=X3IB^04:NVRG88I_#705,4=A`=AZ#I"-)X.XPX#XVM[(WPAC"N8^&X2
M*<K:7<41XYE)Y\BF*3923EI1V_DW2;1$>Q%(ROA)%Z$*&D5))SC?.D4@TA!I
M"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$8;>J!
M4\DP#FM7&(;R\4X]H"*AVKM5@#8CEFX+^*V<I^HQ1_OW#631UE30/!^E44.#
MWCH/2(\W66WD:'!,0M2^^7E.H.UW..K>Q?1YS"9&*L21V[Y$!Z@F#]$1;JD3
M]`&.`&'8-]=U1[U9*0FL:(5]R<1W1IWK2O\`Z)&CH,8/`>7YEM\[*G.3%6@&
M7<'BN$W"DHJ)-Q[O#1;`3\0`'IW#M_'66]O*VH$V4N.*[H\46JH."BD#^.$,
M#P?QAH&$R!(,2*6"VJH^$YLTHDF#A,A@#Q$8YL7N18(F,'7M]LP>D=<;=K]6
D70Z%?)33P2/W/&-M2T3-+BG%SI,22UHXS(-(0:0@TA!I"/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
